In last trading session, Stoke Therapeutics Inc (NASDAQ:STOK) saw 0.88 million shares changing hands with its beta currently measuring 0.97. Company’s recent per share price level of $8.60 trading at $0.49 or 6.04% at ring of the bell on the day assigns it a market valuation of $455.51M. That closing price of STOK’s stock is at a discount of -104.42% from its 52-week high price of $17.58 and is indicating a premium of 34.88% from its 52-week low price of $5.60. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.6 million shares which gives us an average trading volume of 789.90K if we extend that period to 3-months.
For Stoke Therapeutics Inc (STOK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.53 in the current quarter.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Upright in the green during last session for gaining 6.04%, in the last five days STOK remained trading in the green while hitting it’s week-highest on Friday, 03/14/25 when the stock touched $8.60 price level, adding 1.38% to its value on the day. Stoke Therapeutics Inc’s shares saw a change of -22.03% in year-to-date performance and have moved 7.37% in past 5-day. Stoke Therapeutics Inc (NASDAQ:STOK) showed a performance of -16.18% in past 30-days. Number of shares sold short was 11.17 million shares which calculate 13.49 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 18 to the stock, which implies a rise of 52.22% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 18. It follows that stock’s current price would drop -109.3% in reaching the projected high whereas dropping to the targeted low would mean a loss of -109.3% for stock’s current value.
Stoke Therapeutics Inc (STOK) estimates and forecasts
This year revenue growth is estimated to rise 104.06% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.28M for the same. And 5 analysts are in estimates of company making revenue of 7.26M in the next quarter. Company posted 2.8M and 4.22M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -44.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.21% while estimates for its earnings growth in next 5 years are of -0.36%.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Insiders are in possession of 4.67% of company’s total shares while institution are holding 110.52 percent of that, with stock having share float percentage of 115.93%. Investors also watch the number of corporate investors in a company very closely, which is 110.52% institutions for Stoke Therapeutics Inc that are currently holding shares of the company. SKORPIOS TRUST is the top institutional holder at STOK for having 10.84 million shares of worth $146.5 million. And as of 2024-06-30, it was holding 19.445 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 5.41 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.6963 of outstanding shares, having a total worth of $73.08 million.
On the other hand, Vanguard Total Stock Market Index Fund and Blackrock Funds-Health Sciences Opportunity Portfolio are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.57 shares of worth $13.54 million or 2.97% of the total outstanding shares. The later fund manager was in possession of 969.34 shares on Nov 30, 2024 , making its stake of worth around $8.34 million in the company or a holder of 1.83% of company’s stock.
